For example, administration of the PPARγ ligand rosiglitazone reduces foam cell formation and atherosclerosis in LDL-R knockout mice [23], and transplantation of PPARγ-deficient bone marrow into recipient LDL-R knockout mice enhanced atherosclerosis [24]. This evidence concerns the gene LDLR and atherosclerosis.